GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Provexis PLC (FRA:NZCA) » Definitions » Notes Receivable

Provexis (FRA:NZCA) Notes Receivable : €0.00 Mil (As of Sep. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Provexis Notes Receivable?

Provexis's Notes Receivable for the quarter that ended in Sep. 2023 was €0.00 Mil.


Provexis Notes Receivable Historical Data

The historical data trend for Provexis's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Provexis Notes Receivable Chart

Provexis Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Provexis Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Provexis Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Provexis Notes Receivable Related Terms

Thank you for viewing the detailed overview of Provexis's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Provexis (FRA:NZCA) Business Description

Traded in Other Exchanges
Address
2 Blagrave Street, I Ford, Reading, Berkshire, GBR, RG1 1AZ
Provexis PLC is a British food company. It is engaged in developing and licensing the Fruitflow, which is a patented, natural, breakthrough ingredient which helps with platelet aggregation. Fruitflow reduces the propensity for aberrant blood clotting, typically associated with cardiovascular disease, which can result in heart attack and stroke. The extract is available in two formats, a syrup and a powder, and it can be included in a broad range of food, beverage and dietary supplement formats.

Provexis (FRA:NZCA) Headlines

No Headlines